WAIVER AND MODIFICATION NO. 3 TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories • California
This Third Modification and Modification No. 3 under Loan and Security Agreement (this “Third Modification”) is entered into as of August 20, 2018 (the “Third Modification Effective Date”), by and between Partners for Growth IV, L.P. (“PFG”), as lender, and each of (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM, LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of Australia (“Australian Borrower”, and together with Parent, Delaware Subsidiary, and Vivo, jointly and severally, individually and collectively, “Borrower”). Capitalized terms used but not defined in this Third Modification shall have the meanings given them in the Loan Agreement.
WAIVER AND THIRD AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY agreementLoan and Security Agreement • August 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories
This Waiver and Third Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into this 20th day of August, 2018 by and among (a) SILICON VALLEY BANK, a California corporation (“Bank”), and (b) (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM, LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of Australia (“Australian Borrower”, and together with Parent, Delaware Subsidiary, and Vivo, jointly and severally, individually and collectively, “Borrower”).
